首页> 外文期刊>Toxicologic pathology >NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression.
【24h】

NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression.

机译:NSAID诱导的急性期反应归因于肠道通透性的提高,其特征是肝脏基因表达的早期和持续改变。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Toxicogenomics using a reference database can provide a better understanding and prediction of toxicity, largely by creating biomarkers that tie gene expression to actual pathology events. During the course of building a toxicogenomic database, an observation was made that a number of non-steroidal anti-inflammatory compounds (NSAIDs) at supra-pharmacologic doses induced an acute phase response (APR) and displayed hepatic gene expression patterns similar to that of intravenous lipopolysaccharide (LPS). Since NSAIDs are known to cause injury along the gastrointestinal tract, it has been suggested that NSAIDs increase intestinal permeability, allowing LPS and/or bacteria into the systemic circulation and stimulating an APR detectable in the liver. A short term study was subsequently conducted examining the effects of aspirin, indomethacin, ibuprofen, and rofecoxib to rats and a variety of endpoints were examined that included serum levels of inflammatory cytokines, histologic evaluation, and hepatic geneexpression. Both indomethacin and ibuprofen injured the gastrointestinal tract, induced an APR, and increased serum levels of LPS, while rofecoxib and aspirin did not affect the GI tract or induce an APR. In treatments that eventually showed a systemic inflammatory response, hepatic expression of many inflammatory genes was noted as early as 6 hours after treatment well before alterations in traditional clinical pathology markers were detected. This finding led to the creation of a hepatic gene expression biomarker of APR that was effectively shown to be an early identifier of imminent inflammatory injury. In terms of the relative gastrointestinal safety and the NSAIDs studied, an important safety distinction can be made between the presumptive efficacious dose and the APR-inducing dose for indomethacin (1-2-fold), ibuprofen (5-fold), and rofecoxib (approximately 250-fold). Our data support the notion that NSAID-induced intestinal injury results in leakage of commensural bacteria and/or LPS into the circulation, provoking a systemic inflammatory response and that hepatic gene expression-based biomarkers can be used as early and sensitive biomarkers of APR onset.
机译:使用参考数据库的毒物基因组学可以更好地理解和预测毒性,主要是通过创建将基因表达与实际病理事件联系起来的生物标志物来进行。在建立毒理基因组数据库的过程中,观察到许多超药理剂量的非甾体类抗炎化合物(NSAIDs)引起急性期反应(APR),并显示出与肝素相似的肝基因表达模式。静脉内脂多糖(LPS)。由于已知NSAID会引起胃肠道损伤,因此已提出NSAID可增加肠通透性,使LPS和/或细菌进入体循环并刺激肝脏中可检测到的APR。随后进行了一项短期研究,检查了阿司匹林,消炎痛,布洛芬和罗非昔布对大鼠的影响,并检查了包括血清中炎性细胞因子水平,组织学评估和肝基因表达在内的各种终点。吲哚美辛和布洛芬均会损伤胃肠道,引起APR,并升高血清LPS水平,而罗非考昔和阿司匹林则不影响胃肠道或APR。在最终显示出全身性炎症反应的治疗中,许多炎症基因的肝表达早在治疗后6小时就被发现,而且在检测到传统临床病理标志物改变之前。该发现导致了APR的肝基因表达生物标志物的产生,该标志物被有效地证明是即将发生的炎性损伤的早期标识符。就相对胃肠道安全性和所研究的NSAID而言,消炎痛的推定有效剂量和APR诱导剂量(1-2倍),布洛芬(5倍)和罗非考昔(约250倍)。我们的数据支持以下观念:NSAID引起的肠道损伤会导致共生细菌和/或LPS渗入循环系统,引起全身性炎症反应,并且基于肝基因表达的生物标记物可用作APR发作的早期和敏感生物标记物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号